Citigroup
CAPR icon

Citigroup’s Capricor Therapeutics CAPR Stock Holding History

Citigroup’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759K Hold
31,500
– – ﹤0.01% 3645
2026
Q1 		$958K Buy
+31,500
New +$839K ﹤0.01% 3143
2025
Q1 		– Sell
-10,000
Closed -$138K – 5617
2024
Q4 		$138K Buy
+10,000
New +$175K ﹤0.01% 4661

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citigroup's CAPR Position: Q2 2026 in Review

Citigroup increased its Capricor Therapeutics (CAPR) stake by 626% in Q2 2026, buying an estimated $2.09M and bringing the position to 80,123 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

Citigroup first reported a position in CAPR in Q2 2020 and has held it in 16 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Citigroup held 80,123 shares of Capricor Therapeutics worth $1.93M as of Q2 2026.
  • Citigroup bought 69,087 Capricor Therapeutics shares in Q2 2026, an estimated $2.09M.
  • Capricor Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2958 holding.
  • Citigroup first reported a position in Capricor Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.